Paysign Inc. updated its financial outlook during the 17th Annual Midwest IDEAS Conference on August 27, 2026, projecting total revenue of $114 million to $117 million for 2026, a 39% increase from the $82 million reported in 2025.
The company also raised its adjusted EBITDA guidance to $35 million to $38 million for 2026, up from an estimated $19.8 million to $20 million in 2025. Paysign expects gross margins to expand to 60%-62% in 2026, from 59.4% last year, while net income is projected at $21.5 million to $23 million, compared with $5.7 million to $6 million in 2025. Diluted EPS is forecast at $0.35 to $0.37, up from $0.09 to $0.10 in 2025.
Paysign, which operates in plasma payments and patient affordability programs, reported 2025 revenue growth of 40.5% year-over-year. Adjusted EBITDA rose 107% to approximately $19.8 million to $20 million, while net income reached $5.7 million to $6 million. The company maintains zero bank debt and holds over $30 million in unrestricted cash.
In the plasma payments segment, Paysign serves 561 U.S. facilities out of roughly 1,200, managing 8.4 million cardholders and commanding a 45.5% market share. Plasma revenue grew 4% to $44 million in 2025, with 2026 guidance at $57 million, reflecting a 24% increase. The U.S. plasma payment market is estimated at $110 million to $120 million, while the broader plasma software market is projected to expand from $3.5 billion to $7.5 billion over the next decade.
The patient affordability segment, which provides co-pay program management for pharmaceutical companies, saw first-half 2026 revenue rise over 85% year-over-year. Q1 2026 revenue reached $15.7 million, up from $7.8 million, while Q2 2026 revenue was $14.6 million, compared with $7.9 million. Full-year 2026 target is set at about $60 million, up from $34 million in 2025. The segment now supports 157 active programs, with an average revenue per program of just under $100,000 in Q2 2026, a 25% increase year-over-year.
Paysign’s fraud prevention and dynamic business rules saved customers over $325 million in 2025, with year-to-date savings in 2026 exceeding $300 million and full-year expectations surpassing $500 million. The company’s first-fill accuracy stands at 97%.
